LEXINGTON, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company ...

March 11, 2025Voyager Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.59 EPS, expectations were ...

Voyager 1 crossed into interstellar space in 2012, followed by Voyager 2 in 2018, making them the only spacecraft to operate ...

For companies like Voyager, which pivoted from commercial space ventures to national security, the program represents both opportunity and complexity. Previously called Voyager Space, the firm ...

Voyager program scientist at NASA Headquarters in Washington, in a statement. “Every bit of additional data we have gathered since then is not only valuable bonus science for heliophysics ...

The farthest spacecraft from Earth are shutting off instruments in interstellar space, but their mission in interstellar space isn’t over yet ...

To help them conserve energy, mission operators at the agency's Jet Propulsion Laboratory (JPL) are shutting off one ...

Voyager Therapeutics will reassess its gene therapy program for amyotrophic lateral sclerosis (ALS) associated with mutations in the SOD1 gene after its original candidate, VY9323, was found to have ...

All other programs remain on track; IND filings expected in 2025 for GBA1 and FA programs - LEXINGTON, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a ...

US biotech Voyager Therapeutics (Nasdaq: VYGR) saw its shares close down 21% at $4.20 on Tuesday, after it revealed its decision to assess alternate payloads related to its gene therapy program for ...

Voyager program scientist at NASA Headquarters in Washington. "Every bit of additional data we have gathered since then is not only valuable bonus science for heliophysics, but also a testament to ...